Accessibility Menu

Ginkgo Bioworks(OTC) DNABW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-98%
1 Month-50%
$0.00
+0.00%
+0.00Today
Ginkgo Bioworks last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-31
Ginkgo Bioworks stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-50%USD 0.002026-08-24
1 month-50%USD 0.002026-07-31
3 month-85.71%USD 0.002026-06-02
Year to date-96%USD 0.012025-12-31
1 year-98.46%USD 0.012025-08-29
3 year-99.93%USD 0.312023-09-01
5 year-99.99%USD 2.242021-09-01
Since inception-99.99%USD 2.472021-04-19

Ginkgo Bioworks Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$52.76M

Net Income (TTM)

-$290.80M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1.80 (High)

Price

$0.00

Volume

84,628

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.02

Estimated Earnings Date

N/A

DNABW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment consists of end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through the company's two core offerings, Canopy and Horizon. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Industry

Life Sciences Tools and Services

DNABW Financials

Key Financial Metrics (TTM)

Gross Margin

88.36%

Operating Margin

-550.98%

Net Income Margin

-551.19%

Return on Equity

-60.21%

Return on Capital

-34.06%

Return on Assets

-29.37%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

84.63K

Avg. Volume

54.13K

Financials (TTM)

Gross Profit

$46.62M

Operating Income

-$290.69M

EBITDA

-$180.07M

Operating Cash Flow

-$167.89M

Capital Expenditure

-$4.56M

Free Cash Flow

-$172.45M

Cash & ST Invst.

$386.73M

Total Debt

$404.11M

Ginkgo Bioworks Performance Analysis

Ginkgo Bioworks sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-21.7%
Q42025-12-31-14.0%
Q12026-03-31-100.0%
Q22026-06-30N/A
Ginkgo Bioworks sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-31.8%
Q42025-12-312.8%
Q12026-03-311.4%
Q22026-06-3046.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

-$19.47M

-139.3%

Gross Profit

-$8.39M

-120.9%

Gross Margin

43.10%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

-$46.71M

+22.5%

EBITDA

-$58.55M

-30.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$386.73M

-18.4%

Total Debt

$404.11M

-5.8%

Accounts Receivable

$13.01M

-41.3%

Inventory

$0.00

N/A

Long Term Debt

$404.11M

-5.8%

Short Term Debt

$0.00

N/A

Return on Assets

-29.37%

N/A

Return on Invested Capital

-31.69%

N/A

Free Cash Flow

-$44.79M

-11.2%

Operating Cash Flow

-$42.17M

-4.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About DNABW

What is the current price of Ginkgo Bioworks?

Ginkgo Bioworks is trading at $0.00 per share.

What is the 52-week range for Ginkgo Bioworks?

Over the past 52 weeks, Ginkgo Bioworks has traded between $0.00 and $0.02.

How much debt does Ginkgo Bioworks have?

Ginkgo Bioworks total debt is unavailable.

How much cash does Ginkgo Bioworks have on hand?

Ginkgo Bioworks does not have cash on hand data available.

What is Ginkgo Bioworks’s dividend yield?

Ginkgo Bioworks does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.